Centyrin-siRNA Conjugates for the Treatment of Pompe Disease in a new Clinical Trial
Learn about a Phase 1b clinical trial for ABX1100, a substrate reduction therapy (SRT), which aims to slow disease progression.
Aro Biotherapeutics starts Phase 1b Clinical Trial for Substrate Reduction Therapy ABX1100
Aro Biotherapeutics has launched a Phase 1b clinical trial for ABX1100, a substrate reduction therapy (SRT).
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001
This Substrate Reduction Therapy drug could be the first pill taken by mouth to treat Pompe disease.
Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy
Recently, preclinical data were presented at the 18th Annual WORLDSymposium in San Diego, CA, supporting MZE001 as a treatment for Pompe disease.